My Treatment Approach: Androgen Receptor Inhibitors and the Evolving Treatment Paradigm in Castration-Sensitive Prostate Cancer

Stephen J. Freedland, MD, and Eleni Efstathiou, MD, PhD, examine the role of androgen receptor inhibitors, emphasize the significance of early intervention and biomarkers, and evaluate recent developments in the treatment paradigm for castration-sensitive prostate cancer.

EP. 1: Testing Principes and Benefits of Early Intervention in Castration-Sensitive Prostate Cancer

June 26th 2024

Key opinion leaders examine the principles and advantages of early intervention strategies for patients with castration-sensitive prostate cancer.

EP. 2: Risk Stratification and Prognostic Markers in castration-sensitive prostate cancer

June 26th 2024

The panel of prostate cancer experts explores risk stratification methodologies and prognostic markers for castration-sensitive prostate cancer, emphasizing crucial factors that influence patient categorization and treatment decisions.

EP. 3: Evolving Treatment Paradigm and NCCN Guideline Updates

July 3rd 2024

Key opinion leaders examine the treatment landscape for castration-sensitive prostate cancer, highlighting prevalent first-line approaches and discussing the role of androgen deprivation therapy in the treatment paradigm.

EP. 4: The EMBARK trial investigating enzalutamide in NM CSPC

July 3rd 2024

Prostate cancer experts analyze the EMBARK trial, emphasizing the potential impact of an androgen receptor inhibitor in the treatment of non-metastatic castration-sensitive prostate cancer.

EP. 5: The Role of PSA Doubling Time in Risk Assessment

July 10th 2024

Specialists examine non-metastatic castration-sensitive prostate cancer cases, evaluating the significance of PSA doubling time and the reliability of biomarkers in risk assessment for these patients.

EP. 6: Patient Case 1: Non-Metastatic CSPC with Rapidly Doubling PSA

July 10th 2024

Experts present a case study of a patient with non-metastatic castration-sensitive prostate cancer exhibiting rapid PSA doubling, highlighting the clinical implications and potential treatment considerations.

EP. 7: Patient Case 2: Metastatic CSPC

July 17th 2024

Key opinion leaders outline a case study of a patient with metastatic castration-sensitive prostate cancer, detailing the chosen treatment approaches and the overall outcome of the case.

EP. 8: Final Thoughts on CSPC

July 17th 2024

Experts offer concluding remarks on castration-sensitive prostate cancer, sharing their perspectives on the evolving field and expressing their aspirations for future advancements in disease treatment.